Cargando…
The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats
Chronic kidney disease (CKD) progression is associated with persisting oxidative stress, which impairs the NO-sGC-cGMP signaling cascade through the formation of oxidized and heme-free apo-sGC that cannot be activated by NO. Runcaciguat (BAY 1101042) is a novel, potent, and selective sGC activator t...
Autores principales: | Kraehling, Jan R., Benardeau, Agnes, Schomber, Tibor, Popp, Laura, Vienenkoetter, Julia, Ellinger-Ziegelbauer, Heidrun, Pavkovic, Mira, Hartmann, Elke, Siudak, Krystyna, Freyberger, Alexius, Hagelschuer, Ina, Mathar, Ilka, Hueser, Joerg, Hahn, Michael G., Geiss, Volker, Eitner, Frank, Sandner, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488129/ https://www.ncbi.nlm.nih.gov/pubmed/37686032 http://dx.doi.org/10.3390/ijms241713226 |
Ejemplares similares
-
Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease
por: Bénardeau, Agnès, et al.
Publicado: (2021) -
The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective
por: Krishnan, Shalini M., et al.
Publicado: (2018) -
Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution
por: Balzer, Michael S., et al.
Publicado: (2023) -
Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney
por: Stehle, Daniel, et al.
Publicado: (2021) -
Glomerulonephritis-induced changes in kidney gene expression in rats
por: Pavkovic, Mira, et al.
Publicado: (2015)